DUBLIN, Aug. 29, 2023 /PRNewswire/ — The “Global 3D Printed Drugs Market (2023-2028) by Technology, Application, End User, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering.
Global 3D Printed Drugs Market estimated at USD US 74.04 Million In 2023, it is anticipated that the number of people who will be living in poverty worldwide will reach USD 157.46 Million Growth of 16.29% CAGR by 2028.
3D printed pharmaceuticals are created by 3D printers. The new technology allows for precise control over medication composition. This includes complex combinations and customized dosages. To produce the drug, layers of APIs and binders must be printed. 3D printed pharmaceuticals have the potential to revolutionize pharmaceutical manufacturing as well as personalized medicine.
A growing demand for 3D-printed medicines is driven by an increase in the number of immediate soluble products. The 3D-printed drug can dissolve instantly, which makes it easier for patients to take, particularly those who are having difficulty swallowing the medication or need immediate relief. It is possible to develop fast-soluble medications that meet the evolving needs of healthcare professionals and patients.
A third important driver for the market of 3D printed drugs is the growing use of 3D printers in the medical industry. Customizing drug dosage forms with 3D printing allows personalized treatments and improved patient care. Its versatility and ability to create complex structures for drugs makes it an effective tool in drug production and discovery.
A growing number of 3D-printed medicines are also generated by personalized medications and combination medicine production. The 3D-printing process allows the creation of customized medications, with dosages and formulations tailored to specific patient needs. This technique can also be used to create combination drugs, which combine different medications into one printed dosage, simplifying the administration of the drug and improving treatment outcomes. 3D-printed medicines are in demand because of the push towards personalized treatment and combination therapies.
The market for 3D-printed drugs is a promising one, thanks to the constant technological advancements in 3D print processes. As technology advances, the printing resolution and optimization of processes, we can create more accurate and complex drug structures. These improvements will improve treatment efficacy and safety.
As healthcare spending increases in emerging economies, the market for 3D printed pharmaceuticals is likely to grow. They invest in 3D printers and other cutting edge technologies. 3D printing could help improve accessibility, affordability, personalized solutions, and healthcare in these areas.
One limitation of 3D printed medicines is the risk that they may have antagonistic effects. In complex 3D printed drug combinations, the interaction between multiple active pharmaceutical components (APIs), can lead to unexpected interactions and reduced efficacy. This poses issues in terms of drug formulation as well as safety assurance.
Government regulations that are strict for 3D-printed drugs pose a significant challenge to the 3D-printed pharmaceuticals industry. Due to the uniqueness of 3D printing and its personalized components, it is difficult for regulatory agencies to create standards and criteria that are clear and measurable in terms of quality, safety and efficacy. These rules can complicate and prolong the development and commercialization of 3D-printed medicines.
Market Dynamics
Drivers:
- Increased Demand for Instantly Soluble Drugs
- Increasing Use of 3D Printing Techniques in the Medical & Healthcare Industries
- As Personalized Drugs are Increasingly Popularized, the Production of Combination Medicine is Also Growing
Restraints:
- Drugs can have antagonistic effects
Opportunities:
- Technology is always evolving in the 3D printing field
- Increase in Healthcare Investments in Emerging Countries
Challenges:
- Three-dimensional printed goods are subject to strict government regulations
Companies Mentioned:
- 3D Systems, Corp.
- Abbott Laboratories
- Anatomics, Pty. Ltd.
- Aprecia Pharmaceuticals, LLC
- AstraZeneca
- Bioduro-Sundia
- Biomedical modeling, Inc.
- Esko
- FabRx LTD.
- GE Healthcare
- GlaxoSmithKline
- Materialise NV
- Merck Group
- Novartis
- Renishaw PLC
- Siemens Ag
- Stratasys, Ltd.
- Teva Pharmaceuticals Ltd.
- Triastek, Inc.
- Zortrax
The Key Attributes
|
Report Attributes |
The following Details are available: |
|
No. No. |
189 |
|
Forecast Period |
2023 – 2028 |
|
Estimated market value in USD 2023 |
74.04 Million |
|
Forecasted Market value (USD), by 2028 |
$157.46 million |
|
Compound Annual Growth rate |
16.2 % |
|
The Regions that are covered |
Global |
For more information about this report visit https://www.researchandmarkets.com/r/wlho3x
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. Our data includes the most recent information on global and regional markets. We also provide the most up-to-date info about key industries, top companies, and new product trends.
Media Contact:
Research and Markets
Laura WoodSenior Manager
[email protected]
To find out the E.S.T office hours, call +1-917-300-0470
For U.S./CAN Call +1-800-526-8630
To find out the GMT office hours, call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
